ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.630,44
0,41%
S&P 500
5.487,03
0,25%
US Dollar vs BRL
5,4412
0,29%
Bitcoin
65.180,21
-1,96%
Brent Oil
84,785
1,05%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Silverback Therapeutics Inc (SBTX)

  7. Silverback Therapeutics Inc (SBTX) Notícias

SBTX

Silverback Therapeutics (SBTX)

Silverback Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SBTX
DataHoraFonteTítuloCódigoCompanhia
28/06/202317:32Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:SBTXSilverback Therapeutics Inc
15/05/202310:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:SBTXSilverback Therapeutics Inc
08/05/202317:35Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:SBTXSilverback Therapeutics Inc
01/05/202317:42Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:SBTXSilverback Therapeutics Inc
01/05/202317:31Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:SBTXSilverback Therapeutics Inc
23/03/202317:14Edgar (US Regulatory)Annual Report (10-k)NASDAQ:SBTXSilverback Therapeutics Inc
23/02/202318:01GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle InjectorsNASDAQ:SBTXSilverback Therapeutics Inc
22/02/202318:05GlobeNewswire Inc.ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
13/02/202318:33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:SBTXSilverback Therapeutics Inc
09/02/202308:30GlobeNewswire Inc.ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023NASDAQ:SBTXSilverback Therapeutics Inc
17/01/202319:07Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:SBTXSilverback Therapeutics Inc
17/01/202318:31Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:SBTXSilverback Therapeutics Inc
05/01/202319:02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:SBTXSilverback Therapeutics Inc
30/11/202218:24Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:SBTXSilverback Therapeutics Inc
21/11/202218:08Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:SBTXSilverback Therapeutics Inc
10/11/202219:02Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:SBTXSilverback Therapeutics Inc
10/11/202210:00GlobeNewswire Inc.ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
08/11/202218:02GlobeNewswire Inc.ARS Pharmaceuticals Closes Merger with Silverback TherapeuticsNASDAQ:SBTXSilverback Therapeutics Inc
27/10/202217:17Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:SBTXSilverback Therapeutics Inc
21/10/202209:36Dow Jones NewsSilverback Therapeutics' Nasal Spray for Allergic Reactions Gets FDA Review ApprovalNASDAQ:SBTXSilverback Therapeutics Inc
21/10/202208:31Business WireSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including AnaphylaxisNASDAQ:SBTXSilverback Therapeutics Inc
06/10/202217:17Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:SBTXSilverback Therapeutics Inc
11/08/202218:23Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:SBTXSilverback Therapeutics Inc
22/07/202207:15TipRanksAnalysts Offer Insights on Healthcare Companies: Plus Therapeutics (PSTV), Anixa Biosciences (ANIX) and Silverback Therapeutics (SBTX)NASDAQ:SBTXSilverback Therapeutics Inc
21/07/202217:00Business WireSilverback Therapeutics and ARS Pharmaceuticals Announce MergerNASDAQ:SBTXSilverback Therapeutics Inc
18/07/202207:01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:SBTXSilverback Therapeutics Inc
17/05/202217:05Business WireSilverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:SBTXSilverback Therapeutics Inc
15/05/202213:38TipRanksJonesTrading Keeps Their Hold Rating on Silverback Therapeutics (SBTX)NASDAQ:SBTXSilverback Therapeutics Inc
13/05/202209:49TipRanksH.C. Wainwright Keeps a Hold Rating on Silverback Therapeutics (SBTX)NASDAQ:SBTXSilverback Therapeutics Inc
12/05/202217:01Business WireSilverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business UpdateNASDAQ:SBTXSilverback Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SBTX

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HAGA3
HAGA ON
BOV
AZEV4
AZEVEDO PN
BOV
OIBR3
OI ON
BOV
DASA3
DASA ON
BOV
COGN3
COGNA ON
BOV
PRIO3
PETRORIO ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
TPIS3
TRIUNFO PART ON
BOV
SGPS3
SPRINGS ON
BOV
TELB4
TELEBRAS PN
BOV
GOLL4
GOL PN
BOV
AMAR3
LOJAS MARISA ON
BOV
TECN3
TECHNOS ON
BOV
QUAL3
QUALICORP ON
BOV
JHSF3
JHSF PART ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados